More: American Society of Clinical Oncology (ASCO) 44th Annual Meeting

The Emergence of Biomarkers in Treatment for Metastatic Colorectal Cancer: An Expert Interview With Dr. Neal Meropol CME

May 30, 2008 - June 3, 2008, Chicago, Illinois

Author Information and Disclosures

This activity is not sanctioned by, nor a part of, the American Society of Clinical Oncology.

Release Date: June 30, 2008; Valid for credit through June 30, 2009

Credits Available
Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Society of Clinical Oncology. These materials and the related activity are not sanctioned by the American Society of Clinical Oncology or the commercial supporter of the conference and do not constitute an official part of that conference.

Copyright © 2008 Medscape.
Imclone Oncology
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe K-RAS mutation status and its role as a prognostic indicator in patients with mCRC
  2. Review the latest data on the use of EGFR inhibitor therapy in patients with wild-type K-RAS status
  3. Discuss other biomarker studies reported at ASCO 2008 with the potential to help clinicians further personalize treatment for patients with colorectal cancer
Authors and Disclosures

Neal J. Meropol, MD
Disclosure: Neal J. Meropol, MD, has disclosed that he has received grants for clinical research from Genentech. Dr. Meropol has also disclosed that he has served as an advisor or consultant to Genentech, ImClone, Amgen, and Pfizer.


Kate Evans
Disclosure: Kate Evans has disclosed no relevant financial relationships.


Margie Miller
Disclosure: Margie Miller has disclosed no relevant financial relationships.


Jill W. Chamberlain
Disclosure: Jill W. Chamberlain has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.